{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:39:32Z","timestamp":1777952372909,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004916","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Amazonas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004916","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Imatinib mesylate (IM) is the drug of choice for the treatment of chronic myeloid leukemia (CML). However, despite most of the results obtained with this therapy being positive, some patients still present a suboptimal therapeutic response or still develop some type of resistance. Therefore, the aim of this study was to evaluate IM plasma levels in CML patients treated at a referral unit in Manaus and correlate them with variables that might interfere with these levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from 52 patients were obtained through a standardized questionnaire containing clinical, sociodemographic, lifestyle, and use of other medication information, as well as an estimate of therapeutic adherence. Additionally, blood collection was performed to measure the plasma concentration of the drug using the HPLC-UV technique. Molecular studies were done to identify the presence of polymorphism in the ABCG2 C421A membrane transporter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most patients were male with a mean age of 52\u2009\u00b1\u200912.3 years (95% CI 49.0\u201355.9). There was a high variation in drug concentrations in the range from 0 to 4694 ng\/mL, with a mean of 1558.59\u2009\u00b1\u2009989.79 ng\/mL (95% CI 1283.0\u20131834.1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Approximately two-thirds of patients were classified in the drug-level range considered therapeutic, and there was a correlation between plasma concentration and higher molecular response. Additionally, most individuals had the normal genotype for the ABCG2 C421A polymorphism but further studies should be performed to reveal the role of this variable in the outcome of the disease in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241252374","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T19:17:48Z","timestamp":1715023068000},"page":"608-615","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between plasma imatinib levels and response to treatment of chronic myeloid leukemia in patients from Manaus, Brazil"],"prefix":"10.1177","volume":"31","author":[{"given":"Ma\u00edra Ara\u00fajo","family":"Henriques","sequence":"first","affiliation":[{"name":"Universidade Federal do Amazonas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank do Carmo Guedes","family":"J\u00fanior","sequence":"additional","affiliation":[{"name":"Universidade Federal do Amazonas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00edlian Minako","family":"Karube","sequence":"additional","affiliation":[{"name":"Universidade Federal do Amazonas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ros\u00e2ngela Santos","family":"de Abreu","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Amazonas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Pereira de Moura","family":"Neto","sequence":"additional","affiliation":[{"name":"Universidade Federal do Amazonas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-696X","authenticated-orcid":false,"given":"Igor Rafael dos Santos","family":"Magalh\u00e3es","sequence":"additional","affiliation":[{"name":"Universidade Federal do Amazonas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.01.008"},{"key":"e_1_3_2_4_2","first-page":"127","article-title":"Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC","volume":"25","author":"Koren-Michowitz M","year":"2012","unstructured":"Koren-Michowitz M, Volchek Y, Naparstek E, et al. Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC. Hematol Oncol 2012; 25: 127\u2013131.","journal-title":"Hematol Oncol"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00103"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds532"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000324900"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000699"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.30968\/rbfhss.2020.114.0510"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181b2c8cf"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.01.032"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2014.01.009"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12424"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2190-8"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.563885"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000440"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0034-89102012005000013"},{"key":"e_1_3_2_19_2","first-page":"159","article-title":"Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia","volume":"53","author":"Dal Ponte ES","year":"2017","unstructured":"Dal Ponte ES, Wagner SC, Linden R, et al. Study of correlation between imatinib mesylate plasma levels and hematological profile of patients undergoing treatment for chronic myeloid leukemia. J Bras Patol Med Lab 2017; 53: 159\u2013164.","journal-title":"J Bras Patol Med Lab"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.885515"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116475"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0838-3"},{"key":"e_1_3_2_23_2","first-page":"1","article-title":"Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylate in chronic myeloid leukemia patients","volume":"3","author":"Au A","year":"2012","unstructured":"Au A, Ankathil R, Ai-Sim G, et al. Influence of ABCB1 C3435T and ABCG2 C421A gene polymorphisms in response to imatinib mesylate in chronic myeloid leukemia patients. Int J Environ Sci Dev 2012; 3: 1\u20136.","journal-title":"Int J Environ Sci Dev"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2010.98"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241252374","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241252374","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241252374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:50Z","timestamp":1777688990000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241252374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/10781552241252374"],"URL":"https:\/\/doi.org\/10.1177\/10781552241252374","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}